{"id":"https://openalex.org/W2511037992","doi":"https://doi.org/10.1017/s1092852916000365","title":"Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics","display_name":"Effects of aripiprazole once-monthly on symptoms of schizophrenia in patients switched from oral antipsychotics","publication_year":2016,"publication_date":"2016-08-17","ids":{"openalex":"https://openalex.org/W2511037992","doi":"https://doi.org/10.1017/s1092852916000365","mag":"2511037992","pmid":"https://pubmed.ncbi.nlm.nih.gov/27531181"},"language":"en","primary_location":{"id":"doi:10.1017/s1092852916000365","doi":"https://doi.org/10.1017/s1092852916000365","is_oa":false,"landing_page_url":"https://doi.org/10.1017/s1092852916000365","pdf_url":null,"source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019589345","display_name":"Timothy S. Peters-Strickland","orcid":"https://orcid.org/0000-0001-9985-6711","observed_orcids":["https://orcid.org/0000-0001-9985-6711"]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Timothy Peters-Strickland","raw_affiliation_strings":["Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087237583","display_name":"Cathy Yunjia Zhao","orcid":"https://orcid.org/0000-0003-4722-9673","observed_orcids":["https://orcid.org/0000-0003-4722-9673"]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cathy Zhao","raw_affiliation_strings":["Biostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082491959","display_name":"Pamela P. Perry","orcid":"https://orcid.org/0000-0002-1203-123X","observed_orcids":["https://orcid.org/0000-0002-1203-123X"]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela P. Perry","raw_affiliation_strings":["Clinical Management and Corporate Projects, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Management and Corporate Projects, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042720237","display_name":"Anna Eramo","orcid":"https://orcid.org/0000-0002-4289-0975","observed_orcids":["https://orcid.org/0000-0002-4289-0975"]},"institutions":[{"id":"https://openalex.org/I4210150391","display_name":"Lundbeck (United States)","ror":"https://ror.org/04a2yjk98","country_code":"US","type":"company","lineage":["https://openalex.org/I133593841","https://openalex.org/I4210150391"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna Eramo","raw_affiliation_strings":["Medical Affairs & Phase IV Clinical Affairs, Lundbeck LLC, Deerfield, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs & Phase IV Clinical Affairs, Lundbeck LLC, Deerfield, IL, USA","institution_ids":["https://openalex.org/I4210150391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114029347","display_name":"Phyllis M. Salzman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phyllis M. Salzman","raw_affiliation_strings":["Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108358185","display_name":"Robert D. McQuade","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert D. McQuade","raw_affiliation_strings":["Executive Vice President and Chief Strategic Officer, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Executive Vice President and Chief Strategic Officer, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023289701","display_name":"Brian R. Johnson","orcid":"https://orcid.org/0000-0002-8279-0004","observed_orcids":["https://orcid.org/0000-0002-8279-0004"]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian R. Johnson","raw_affiliation_strings":["Clinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045081626","display_name":"Raymond Sanchez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raymond Sanchez","raw_affiliation_strings":["Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Clinical Development, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5019589345"],"corresponding_institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"],"apc_list":{"value":3550,"currency":"USD","value_usd":3550},"apc_paid":null,"fwci":1.3797,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.8037869,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"21","issue":"6","first_page":"460","last_page":"465"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12308","display_name":"Mental Health and Psychiatry","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1211","display_name":"Philosophy"},"field":{"id":"https://openalex.org/fields/12","display_name":"Arts and Humanities"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aripiprazole-once-monthly","display_name":"aripiprazole once-monthly","score":0.984000027179718},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.8920000195503235},{"id":"https://openalex.org/keywords/antipsychotic-switching","display_name":"antipsychotic switching","score":0.8240000009536743},{"id":"https://openalex.org/keywords/oral-antipsychotics","display_name":"oral antipsychotics","score":0.8939999938011169},{"id":"https://openalex.org/keywords/long-acting-injectable-antipsychotics","display_name":"long-acting injectable antipsychotics","score":0.8870000243186951},{"id":"https://openalex.org/keywords/positive-and-negative-syndrome-scale","display_name":"PANSS","score":0.7160000205039978},{"id":"https://openalex.org/keywords/cgi-s","display_name":"CGI-S","score":0.6629999876022339},{"id":"https://openalex.org/keywords/clinical-global-impression-improvement","display_name":"CGI-I","score":0.8889999985694885},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.6579999923706055},{"id":"https://openalex.org/keywords/community-based-treatment","display_name":"community-based treatment","score":0.3070000112056732}],"concepts":[{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.9489530324935913},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.7140163779258728},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5980033874511719},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5009992122650146},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.333577036857605}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003692","descriptor_name":"Delayed-Action Preparations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012565","descriptor_name":"Schizophrenic Psychology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1017/s1092852916000365","doi":"https://doi.org/10.1017/s1092852916000365","is_oa":false,"landing_page_url":"https://doi.org/10.1017/s1092852916000365","pdf_url":null,"source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},{"id":"pmid:27531181","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27531181","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS spectrums","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W1919551764","https://openalex.org/W1976152446","https://openalex.org/W1977536404","https://openalex.org/W1986011584","https://openalex.org/W1997645519","https://openalex.org/W2001047461","https://openalex.org/W2003289380","https://openalex.org/W2009652756","https://openalex.org/W2036064147","https://openalex.org/W2037650878","https://openalex.org/W2058717107","https://openalex.org/W2070161080","https://openalex.org/W2088866491","https://openalex.org/W2104819369","https://openalex.org/W2107201157","https://openalex.org/W2138418531","https://openalex.org/W2140606211","https://openalex.org/W2143285031","https://openalex.org/W2157910519","https://openalex.org/W2916996048","https://openalex.org/W3090293687"],"related_works":["https://openalex.org/W2901153435","https://openalex.org/W3002876138","https://openalex.org/W4410463009","https://openalex.org/W2001047461","https://openalex.org/W3154069077","https://openalex.org/W4288341577","https://openalex.org/W2130156045","https://openalex.org/W2920967104","https://openalex.org/W1996205985","https://openalex.org/W4205446244"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"assess":[2],"the":[3,97,169,172],"effects":[4],"of":[5,44,96,127,140,171,175],"aripiprazole":[6,81],"once-monthly":[7],"400":[8,66,89,100,199],"mg":[9],"(AOM":[10],"400)":[11],"on":[12],"clinical":[13,207],"symptoms":[14],"and":[15,41,104,112,115,125,153,160,195],"global":[16],"improvement":[17,163],"in":[18,34,54,102,133,206],"schizophrenia":[19,37,189],"after":[20,67],"switching":[21,68],"from":[22,69,94,131,157,200],"an":[23],"oral":[24,71,80,201],"antipsychotic.":[25],"METHODS:":[26],"In":[27,183],"a":[28,184],"multicenter,":[29],"open-label,":[30],"mirror-image,":[31],"naturalistic":[32],"study":[33],"patients":[35,76,176,187],"with":[36,64,188],"(>1":[38],"year,":[39],"Diagnostic":[40],"Statistical":[42],"Manual":[43],"Mental":[45],"Disorders,":[46],"Fourth":[47],"Edition,":[48],"Text":[49],"Revision":[50],"[DSM-IV-TR]":[51],"criteria),":[52],"changes":[53],"efficacy":[55],"measures":[56],"were":[57,77,149,177,191],"assessed":[58],"during":[59],"prospective":[60,74],"treatment":[61],"(6":[62],"months)":[63],"AOM":[65,88,99,198],"standard-of-care":[70],"antipsychotics.":[72],"During":[73],"treatment,":[75],"cross-titrated":[78],"to":[79,197],"monotherapy":[82],"(1-4)":[83],"weeks":[84],"followed":[85],"by":[86],"open-label":[87,98],"(24":[90],"weeks).":[91],"Mean":[92],"change":[93],"baseline":[95,132,158,194],"phase":[101],"Positive":[103],"Negative":[105],"Syndrome":[106],"Scale":[107],"(PANSS)":[108],"scores":[109,155],"(total,":[110],"positive":[111],"negative":[113],"subscales)":[114],"Clinical":[116],"Global":[117],"Impression-Severity":[118],"(CGI-S)":[119],"scores;":[120],"mean":[121],"CGI-Improvement":[122],"(CGI-I)":[123],"score;":[124],"proportion":[126],"responders":[128],"(\u226530%":[129],"decrease":[130],"PANSS":[134,152,178],"total":[135],"score":[136,139],"or":[137,145,179],"CGI-I":[138,161,180],"1":[141],"[very":[142],"much":[143],"improved]":[144],"2":[146],"[much":[147],"improved])":[148],"assessed.":[150],"RESULTS:":[151],"CGI-S":[154],"improved":[156],"(P<0.0001)":[159],"demonstrated":[162],"at":[164,193],"all":[165],"time":[166],"points.":[167],"By":[168],"end":[170],"study,":[173],"49.0%":[174],"responders.":[181],"CONCLUSIONS:":[182],"community":[185],"setting,":[186],"who":[190],"stabilized":[192],"switched":[196],"antipsychotics":[202],"showed":[203],"clear":[204],"improvements":[205],"symptoms.":[208]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-09-16T00:00:00"}